AbbVie
ABBV
S$245.99
Share price
0.43%
Change (1 day)
4.80%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : S$173.12 Billion
According to AbbVie's latest financial reports the company's total liabilities are S$173.12 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
AbbVie - Total liabilities on balance sheet (from 2011 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | S$179.14 B | 9.12% |
| 2023-12-31 | S$164.18 B | 0.78% |
| 2022-12-31 | S$162.90 B | -8.08% |
| 2021-12-31 | S$177.22 B | -2.55% |
| 2020-12-31 | S$181.86 B | 38.66% |
| 2019-12-31 | S$131.16 B | 41.61% |
| 2018-12-31 | S$92.62 B | 5.42% |
| 2017-12-31 | S$87.85 B | -1.23% |
| 2016-12-31 | S$88.95 B | 28.07% |
| 2015-12-31 | S$69.46 B | 103.98% |
| 2014-12-31 | S$34.05 B | 8.79% |
| 2013-12-31 | S$31.30 B | 8.25% |
| 2012-12-31 | S$28.91 B | 194.21% |
| 2011-12-31 | S$9.82 B | 40.47% |
| 2010-12-31 | S$6.99 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | S$150.87 B | -12.85% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$96.36 B | -44.34% | 🇺🇸 USA |
 Eli Lilly LLY | S$94.51 B | -45.40% | 🇺🇸 USA |
 Amgen AMGN | S$106.88 B | -38.26% | 🇺🇸 USA |
 Gilead Sciences GILD | S$48.01 B | -72.27% | 🇺🇸 USA |
 Biogen BIIB | S$14.20 B | -91.79% | 🇺🇸 USA |
 GlaxoSmithKline GSK | S$78.13 B | -54.87% | 🇬🇧 UK |
 AstraZeneca AZN | S$83.69 B | -51.66% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | S$1.48 B | -99.14% | 🇺🇸 USA |